AU2004274017B2 - Modafinil modified release pharmaceutical compositions - Google Patents

Modafinil modified release pharmaceutical compositions Download PDF

Info

Publication number
AU2004274017B2
AU2004274017B2 AU2004274017A AU2004274017A AU2004274017B2 AU 2004274017 B2 AU2004274017 B2 AU 2004274017B2 AU 2004274017 A AU2004274017 A AU 2004274017A AU 2004274017 A AU2004274017 A AU 2004274017A AU 2004274017 B2 AU2004274017 B2 AU 2004274017B2
Authority
AU
Australia
Prior art keywords
modafinil
pharmaceutical composition
compound
release
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004274017A
Other languages
English (en)
Other versions
AU2004274017A1 (en
Inventor
Alpa Parikh
Piyush R. Patel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cephalon LLC
Original Assignee
Cephalon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34381093&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2004274017(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon LLC filed Critical Cephalon LLC
Publication of AU2004274017A1 publication Critical patent/AU2004274017A1/en
Application granted granted Critical
Publication of AU2004274017B2 publication Critical patent/AU2004274017B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AU2004274017A 2003-09-18 2004-09-20 Modafinil modified release pharmaceutical compositions Ceased AU2004274017B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US50402803P 2003-09-18 2003-09-18
US60/504,028 2003-09-18
US10/944,528 2004-09-17
US10/944,528 US8153159B2 (en) 2003-09-18 2004-09-17 Modafinil modified release pharmaceutical compositions
PCT/US2004/030815 WO2005027890A1 (en) 2003-09-18 2004-09-20 Modafinil modified release pharmaceutical compositions

Publications (2)

Publication Number Publication Date
AU2004274017A1 AU2004274017A1 (en) 2005-03-31
AU2004274017B2 true AU2004274017B2 (en) 2010-07-08

Family

ID=34381093

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004274017A Ceased AU2004274017B2 (en) 2003-09-18 2004-09-20 Modafinil modified release pharmaceutical compositions

Country Status (20)

Country Link
US (1) US8153159B2 (cg-RX-API-DMAC10.html)
EP (1) EP1670447B1 (cg-RX-API-DMAC10.html)
JP (1) JP5138932B2 (cg-RX-API-DMAC10.html)
KR (1) KR20060117910A (cg-RX-API-DMAC10.html)
AR (1) AR046410A1 (cg-RX-API-DMAC10.html)
AT (1) ATE448780T1 (cg-RX-API-DMAC10.html)
AU (1) AU2004274017B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0414299A (cg-RX-API-DMAC10.html)
CA (1) CA2536666C (cg-RX-API-DMAC10.html)
DE (1) DE602004024220D1 (cg-RX-API-DMAC10.html)
EA (1) EA011400B1 (cg-RX-API-DMAC10.html)
ES (1) ES2336215T3 (cg-RX-API-DMAC10.html)
IL (1) IL173738A (cg-RX-API-DMAC10.html)
IS (1) IS2787B (cg-RX-API-DMAC10.html)
MX (1) MXPA06003125A (cg-RX-API-DMAC10.html)
MY (1) MY144755A (cg-RX-API-DMAC10.html)
NO (1) NO20060964L (cg-RX-API-DMAC10.html)
NZ (1) NZ545573A (cg-RX-API-DMAC10.html)
TW (1) TWI344840B (cg-RX-API-DMAC10.html)
WO (1) WO2005027890A1 (cg-RX-API-DMAC10.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142896A0 (en) * 1998-11-02 2002-04-21 Elan Corp Plc Multiparticulate modified release composition
ATE483455T1 (de) 2004-05-28 2010-10-15 Transform Pharmaceuticals Inc Mischkristalle sowie sie enthaltende pharmazeutische zusammensetzungen
US20060121112A1 (en) * 2004-12-08 2006-06-08 Elan Corporation, Plc Topiramate pharmaceutical composition
US20100136106A1 (en) * 2005-06-08 2010-06-03 Gary Liversidge Modified Release Famciclovir Compositions
BRPI0707736A2 (pt) 2006-02-13 2011-05-10 Vanda Pharmaceuticals Inc formulaÇÕes de imidazolilalquil-piridinas de dosagem estÁvel
JP2009543803A (ja) * 2006-07-12 2009-12-10 エラン・ファルマ・インターナショナル・リミテッド モダフィニルのナノ粒子製剤
DE102006035549A1 (de) 2006-07-27 2008-01-31 Evonik Röhm Gmbh Arzneiform mit mindestens zweischichtiger Trennschicht
US20090082461A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched modafinil
JP5250285B2 (ja) * 2008-03-26 2013-07-31 富士フイルム株式会社 経口物用被覆材、可食性容器およびそれらを用いた経口物
WO2010012407A1 (en) * 2008-07-29 2010-02-04 Ashland Licensing And Intellectual Property Llc. Modified additives for suppressing dust formation
JP2013530220A (ja) * 2010-07-06 2013-07-25 ナビファーム.カンパニー リミテッド ダポキセチンを含む時間差徐放性経口投与型の薬学的組成物
US8999393B1 (en) * 2013-01-09 2015-04-07 Edgemont Pharmaceuticals Llc Sustained release formulations of lorazepam
CA2947528C (en) 2014-05-01 2023-09-05 Sun Pharmaceutical Industries Limited Extended release suspension compositions
WO2017058869A1 (en) 2015-09-29 2017-04-06 Acorda Therapeutics, Inc. Sustained release compositions of 4-aminopyridine
MY200542A (en) * 2017-07-10 2024-01-02 Takeda Pharmaceuticals Co Preparation comprising vonoprazan

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010038863A1 (en) * 2000-02-23 2001-11-08 Christof Jaenicke Pharmaceutical with predetermined activity profile
US6346548B1 (en) * 1999-08-16 2002-02-12 Cephalon, Inc. Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
WO2002096401A1 (en) * 2001-05-25 2002-12-05 Cephalon, Inc. Solid pharmaceutical formulations comprising modafinil

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534263A (en) * 1995-02-24 1996-07-09 Alza Corporation Active agent dosage form comprising a matrix and at least two insoluble bands
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6492396B2 (en) 2000-05-16 2002-12-10 Cephalon, Inc. Substituted thioacetamides
US6489363B2 (en) * 2000-10-11 2002-12-03 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
US6344215B1 (en) 2000-10-27 2002-02-05 Eurand America, Inc. Methylphenidate modified release formulations
US7141555B2 (en) 2000-12-19 2006-11-28 Cephalon, Inc. Modafinil compound and cyclodextrin mixtures
GB0117618D0 (en) 2001-07-19 2001-09-12 Phoqus Ltd Pharmaceutical dosage form
US7229644B2 (en) * 2002-05-23 2007-06-12 Cephalon, Inc. Pharmaceutical formulations of modafinil
US20040116532A1 (en) 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346548B1 (en) * 1999-08-16 2002-02-12 Cephalon, Inc. Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
US20010038863A1 (en) * 2000-02-23 2001-11-08 Christof Jaenicke Pharmaceutical with predetermined activity profile
WO2002096401A1 (en) * 2001-05-25 2002-12-05 Cephalon, Inc. Solid pharmaceutical formulations comprising modafinil

Also Published As

Publication number Publication date
MY144755A (en) 2011-10-31
EA200600590A1 (ru) 2006-08-25
TWI344840B (en) 2011-07-11
NO20060964L (no) 2006-04-18
US8153159B2 (en) 2012-04-10
IS8327A (is) 2006-02-23
ES2336215T3 (es) 2010-04-09
CA2536666A1 (en) 2005-03-31
KR20060117910A (ko) 2006-11-17
EP1670447B1 (en) 2009-11-18
AR046410A1 (es) 2005-12-07
EA011400B1 (ru) 2009-02-27
AU2004274017A1 (en) 2005-03-31
ATE448780T1 (de) 2009-12-15
NZ545573A (en) 2010-02-26
US20050095294A1 (en) 2005-05-05
WO2005027890A1 (en) 2005-03-31
JP5138932B2 (ja) 2013-02-06
DE602004024220D1 (de) 2009-12-31
IL173738A0 (en) 2006-07-05
HK1089697A1 (en) 2006-12-08
BRPI0414299A (pt) 2006-11-14
EP1670447A1 (en) 2006-06-21
IS2787B (is) 2012-06-15
IL173738A (en) 2012-07-31
TW200520748A (en) 2005-07-01
CA2536666C (en) 2012-06-19
JP2007518696A (ja) 2007-07-12
MXPA06003125A (es) 2006-06-20

Similar Documents

Publication Publication Date Title
JP5622773B2 (ja) テトラサイクリンの1日1回製剤
US20190008758A1 (en) Lacosamide controlled release formulation
CA2536666C (en) Modafinil modified release pharmaceutical compositions
US10149818B2 (en) Daily formulation of lacosamide
CN101784266B (zh) 氢溴酸安非他酮以及治疗的应用
CN1607947A (zh) 包含3-(3-二甲基氨基-1-乙基-2-甲基-丙基)苯酚并能提供活性成分的延迟释放的药物
KR101858797B1 (ko) 히드로모르폰 및 날록손을 포함하는 제약 조성물
JP2013501810A (ja) 医薬組成物
JP2012500221A (ja) Cns障害の処理及び予防のための胃保持性医薬組成物
WO2007054976A2 (en) Lipid based controlled release pharmaceutical composition
US20100003322A1 (en) Enteric coated hydrophobic matrix formulation
KR20080013927A (ko) 벤라팍스의 하나 이상 형태의 개질 방출 조성물
CN101031290B (zh) 改良释放的莫达非尼药物组合物
HK1089697B (en) Modafinil modified release pharmaceutical compositions
KR20170001545A (ko) 모사프리드 서방성 제제 및 모사프리드와 라베프라졸의 복합제제
JP2026026229A (ja) 腸溶性の粒状物及びそれを含有する固形製剤
WO2015150948A1 (en) Modified release solid oral pharmaceutical compositions of cyclobenzaprine or a salt thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired